MSU awarded $20M grant for quantum technology development
kbzk.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kbzk.com Daily Mail and Mail on Sunday newspapers.
MSU awarded $20M grant for quantum technology development
kxlf.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kxlf.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Celsion Corporation Provides Clinical Update on Phase I/II OVATION 2 Study with GEN-1 in .
Celsion CORPFebruary 25, 2021 GMT
Of 27 patients who completed interval debulking surgery, 80% of those treated with GEN-1 had an R0 resection compared with 58% of control patients, a 38% improvement
To date 34 patients, or approximately one-third of the total, have been enrolled at 22 sites, including 20 patients in the treatment arm and 14 patients in the control arm
LAWRENCEVILLE, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today provided an update on its Phase I/II OVATION 2 Study with GEN-1 in patients with advanced ovarian cancer, including interim observations. GEN-1 is Celsion’s DNA-mediated interleukin-12 (IL-12) immunotherapy designed using TheraPlas, it